Table 1 Feasibility outcomes
Trial feasibility measure—proportion of… | Percentage (n/total N) | 95% confidence interval |
|---|---|---|
Patients screened as eligible (Bristol) | 39.2% (71/181) | [32.1, 46.7] |
Patients screened as eligible (London) | 13.1% (78/595) | [10.5, 16.1] |
Eligible patients consented | 34.9% (52/149) | [27.2, 43.1] |
Consented participants randomised | 65.4% (34/52) | [50.9, 78.0] |
Randomised participants with baseline questionnaire data | 91.2% (31/34) | [76.3, 98.1] |
Randomised participants with 3-month questionnaires | 67.6% (23/34) | [49.5, 82.6] |
Surviving randomised participants with 6-month questionnaires | 55.9% (19/34) | [37.9, 72.8] |
Group 1 participants with 15-month questionnaires | 55.5% (5/9) | [21.2, 86.3] |
Participants with baseline, 3- and 6-month questionnaire data | 55.9% (19/34) | [37.9, 72.8] |